Physician Views: Key growth-driver watch - Dupixent

Continued uptake of the IL-4/IL-13 inhibitor Dupixent is critical to the future growth performance of partners Regeneron Pharmaceuticals and Sanofi. This will be driven by broader usage in its approved indication of moderate-to-severe atopic dermatitis (AD), expansion of its AD label into adolescent patients (based on positive Phase III data) and its potential approval (later this year) for the treatment of severe asthma.

Approved in the US for AD in March 2017, we are snap-polling US dermatologists just over a year later to gauge sentiment towards the brand based on real-world use, satisfaction with patient access and the potential impact of labelling for use in adolescent patients. 

Versus pre-launch expectations, what is your assessment of Dupixent (dupilumab) as a treatment for moderate-to-severe AD?




Very good


How satisfied are you with patients' prescribed Dupixent getting access to the therapy?

Not at all satisfied

Slightly satisfied


Very satisfied

Extremely satisfied

How do you expect your utilisation of Dupixent in adults with moderate-to-severe AD to evolve over the next 12 months?

Decline significantly


Stay the same


Increase significantly

New data from a 251-patient Phase III trial assessing Dupixent in patients aged 12 to 17 with moderate-to-severe AD showed that 24 percent of patients who received Dupixent every two weeks and 18 percent of those given the drug every four weeks achieved the primary endpoint (an Investigator's Global Assessment (IGA) score, which measures the overall severity of skin lesions, of 0 or 1 at week 16) compared with 2 percent for placebo.

Further, 41.5 percent of patients who received Dupixent every two weeks and 38 percent administered the therapy every four weeks achieved EASI-75 (75 percent or greater skin improvement), versus 8 percent with placebo. Dupixent's safety profile was consistent with that seen in adults, with the overall rate of adverse events being 72 percent in patients given the drug every two weeks, 64 percent for those dosed every four weeks and 69 percent for placebo.

Taking into account unmet need in adolescent patients, what is your assessment of these data?




Very good


If approved, at what speed do you think Dupixent will be utilised in adolescent AD patients?

Very slowly




Very quickly

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at

To read more Physician Views articles, click here.